Allergic Rhinitis. Allergic rhinitis due to pollen
Conditions
Interventions
Intervention 1: phototherapy1- Prior to the beginning of treatment we should prove whether the patients are really suffering from seasonal allergic rhinitis. If the allergen responsible for the induct
Treatment - Other
Treatment - Drugs
phototherapy1- Prior to the beginning of treatment we should prove whether the patients are really suffering from seasonal allergic rhinitis. If the allergen responsible for the induction of symptoms
In second group: placebo phototherapy (420 nm wavelength filter used to cut UV light) patients receive only visible light and don't receive UV- A or UV-B. Doses and interval of phototherapy : For alle
4th time: 2 minutes and 45 seconds 5th time:3 minutes, 6th time:3 minutes.
Sponsors
Vice chancellor for Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria:1-Men and women 18 – 60 years of age; 2-Out-patients, with a history and diagnosis of allergic rhinitis for at least two years prior to Visit 1; 3-Allergy verified by a positive skin-prick test or specific IgE determination within two years prior to visit 1, or at visit 1; 4-Patients have allergic rhinitis with no response to previous local or systemic antihistamines/corticosteroids, or patients do not want these therapeutic measures or can 't be treated with these drugs due to side effects or any other reasons; 5-Patients having severe disease, where the global severity score was more than 6 in the 10 point scale in the last 3 days before enrollment; 6-Signed Informed Consent obtained from the patient prior to conducting any study-related procedures; Exclusion Criteria:1-Known light-induced skin disease (photodermatosis); 2-Ongoing fungal, viral or bacterial respiratory infection; 3-Anatomic abnormalities in the nose (eg: severe septum deviation or polyps) that disturb photo therapeutically treatment, as judged by the Investigator; 4-Prohibited Medicines such as Digoxin, Doxepin, Amiodarone, Trimethoprim , Chlorpropamide, Piroxicam, Doxycycline, Promethazine all can cause photosensitivity and Wash-Out Periods for PHOTO-SENSITIZING MEDICATIONS (eg: Systemic corticosteroids: 4 weeks; Intranasal Cromolyn, Intranasal and topical corticosteroids: 2 weeks; Intranasal decongestants: 3 days; Intranasal or systemic antihistamines: 1 week; Immunotherapy: 5 years) before beginning the study; 5-Patients less than 18 years old; 6-Pregnant women; 7-Patients unable to give informed consent because of age, mental illness, dementia or communication difficulties and patients with nasopharyngeal tumors all are excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sneezing. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms,1: mild, 2: medium, 3: severe.;Nasal obstruction. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms,1: mild, 2: medium, 3: severe.;Nasal itching. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms,1: mild, 2: medium, 3: severe.;Rhinorrhea. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms, 1: mild, 2: medium, 3: severe.;Total nasal scores. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms, 1: mild, 2: medium, 3: severe.;Eye smyptoms. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms,1: mild, 2: medium, 3: severe.;Itching of the palate,. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms, 1: mild, 2: medium, 3: severe.;Global severity scores questionaries. Timepoint: Day 0, 1, 4, 7, 9, 11, 14, 6th week , third month. Method of measurement: 0: no symptoms,1: mild, 2: medium, 3: severe. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1- Limited activity. Timepoint: 1- Pretreatment, 2- First month, 3- Third month. Method of measurement: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Not impaired at all: 0, severely impaired: 6.;2- Sleep. Timepoint: 1- Pretreatment, 2- First month, 3- Third month. Method of measurement: Rhinoconjunctivitis quality of life questionnaire (RQLQ) scores, Not impaired at all: 0, severely impaired: 6.;3- Non-hay fever symptoms. Timepoint: 1- Pretreatment, 2- First month, 3- Third month. Method of measurement: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Not impaired at all: 0, severely impaired: 6.;4- Practical problems. Timepoint: 1- Pretreatment, 2- First month, 3- Third month. Method of measurement: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Not impaired at all: 0, severely impaired: 6.;5- Nasal symptoms. Timepoint: 1- Pretreatment 2- First month 3- Third month. Method of measurement: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Not impaired at all: 0, severely impaired: 6.;6- Eye symptoms. Timepoint: 1- Pretreatment, 2- First month, 3- Third month. Method of measurement: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Not impaired at all: 0, severely impaired: 6.;7 - Emotional functions. Timepoint: 1- Pretreatment, 2- First month, 3- Third month. Method of measurement: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Not impaired at all: 0, severely impaired: 6. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoushmand Hamidreza
Pediatric allergy and clinical immunology ward
Outcome results
None listed